Embecta (EMBC) Stock
NASDAQ · EMBC
Key stats
- Market cap
- $369.99M
- Price / Earnings ratio
- 4.2x
- EPS (TTM)
- $1.50
- Volume
- Loading
- 52-week high
- $14.91
- 52-week low
- $2.77
- Dividend yield
- 4.90%
- Dividend amount (latest)
- $0.01
- EPS vs analyst estimate
- +8.7%Q4 FY25 · $0.50 vs $0.46
- Next earnings report
- 24 Nov 2026
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with EMBC
Recent news
Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
EMBCAugust 17, 2026
Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
EMBC
Business Wire
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
EMBCAugust 17, 2026
Business Wire
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
EMBC
Business Wire
EMBC Deadline: Rosen Law Firm Urges Embecta Corp. (NASDAQ: EMBC) Stockholders to Contact the Firm for Information About Their Rights
EMBCAugust 13, 2026
Business Wire
EMBC Deadline: Rosen Law Firm Urges Embecta Corp. (NASDAQ: EMBC) Stockholders to Contact the Firm for Information About Their Rights
EMBC
MarketBeat
Embecta Q3 Earnings Call Highlights
EMBCAugust 7, 2026
MarketBeat
Embecta Q3 Earnings Call Highlights
EMBCTechnical indicators
- RSI 14
- 56.91
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.17
- MACD histogram
- -0.04
- SMA 50
- $5.94
- Price above SMA 50
- EMA 50
- $5.93
- Price above EMA 50
- SMA 200
- $6.22
- Price above SMA 200
- EMA 200
- $7.12
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
1B923M461M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
2B2B806M0
Revenue to Profit
2025$1.1B
Revenue$0.0
Cost of revenue$676.8M
Gross profit$0.0
Operating expenses$95.4M
Net incomeEarnings
EPS forecast
Actual EPS
$0.50
$0.46
Q4FY25
$0.67
Q1FY26
$0.67
Q2FY26
Q3FY26
Q4FY26
The market has no earnings per share expectations for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
EMBCAugust 17, 2026
Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
EMBCBusiness Wire
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
EMBCAugust 17, 2026
Business Wire
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
EMBCBusiness Wire
EMBC Deadline: Rosen Law Firm Urges Embecta Corp. (NASDAQ: EMBC) Stockholders to Contact the Firm for Information About Their Rights
EMBCAugust 13, 2026
Business Wire
EMBC Deadline: Rosen Law Firm Urges Embecta Corp. (NASDAQ: EMBC) Stockholders to Contact the Firm for Information About Their Rights
EMBCMarketBeat
Embecta Q3 Earnings Call Highlights
EMBCAugust 7, 2026
MarketBeat
Embecta Q3 Earnings Call Highlights
EMBC
Business Wire
Robbins LLP Reminds EMBC Stockholders of the Securities Fraud Class Action; Contact the Firm for Information About Your Rights
EMBCJuly 16, 2026
Business Wire
Robbins LLP Reminds EMBC Stockholders of the Securities Fraud Class Action; Contact the Firm for Information About Your Rights
EMBC
Business Wire
EMBC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Embecta Corp. Securities Lawsuit - Contact Levi & Korsinsky
EMBCJuly 16, 2026
Business Wire
EMBC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Embecta Corp. Securities Lawsuit - Contact Levi & Korsinsky
EMBC
Business Wire
EMBC Fraud Notice: Embecta Investors are Reminded to Contact BFA Law about the Filed Securities Fraud Class Action Lawsuit to Recover Investment Losses
EMBCJuly 16, 2026
Business Wire
EMBC Fraud Notice: Embecta Investors are Reminded to Contact BFA Law about the Filed Securities Fraud Class Action Lawsuit to Recover Investment Losses
EMBC
Business Wire
Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
EMBCJune 26, 2026
Business Wire
Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
EMBC
Business Wire
Deadline Approaching: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
EMBCJune 25, 2026
Business Wire
Deadline Approaching: Embecta Corp. (EMBC) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
EMBC
Business Wire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Embecta Corp. (EMBC) Shareholders To Inquire About Securities Fraud Class Action
EMBCJune 24, 2026
Business Wire
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Embecta Corp. (EMBC) Shareholders To Inquire About Securities Fraud Class Action
EMBCAbout Embecta
Empowered by nearly 100 years of innovation and a sense of urgency to advance diabetes care, embecta is singularly focused on improving the lives of people living with diabetes. Every time someone starts insulin therapy, they begin a lifelong journey that's shared with millions of people around the globe. Whether you’re a person living with diabetes or helping someone else manage it, embecta is here to support you along the way. We helped set the standard of care in insulin delivery — and through strong community partnerships, innovative technology and comprehensive care resources, we aspire to advance that standard every single day.
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees1,850
CEOMr. Devdatt Kurdikar Ph.D.
IPO DateApr 1, 2022
HeadquartersParsippany, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Devdatt Kurdikar Ph.D. | President, CEO & Chairman | 1969 |
| Mr. Jacob P. Elguicze | Senior VP & CFO | 1973 |
| Mr. Jeffrey Z. Mann | Senior VP, General Counsel, Head of Business Development & Corporate Secretary | 1972 |
| Ms. Jean M. Casner | Senior VP & Chief Human Resources Officer | 1958 |
| Mr. Shaun Curtis | Senior Vice President of Global Manufacturing & Supply Chain | 1970 |
| Mr. Anthony M. Roth | VP, Chief Accounting Officer & Corporate Controller | 1973 |
| Mr. Pravesh Khandelwal | VP & Head of Investor Relations | — |
| Ms. Ginny Blocki | Senior Vice President of Strategy | — |
| Mr. Tom Blount | Senior VP & President of North America | 1974 |
| Mr. Slobodan Radumilo | Senior VP & President of International | 1971 |
Fundamentals
Valuation
Price-to-sales ratio0.35
Price-to-book value-0.59
Profitability
Return on Equity-14.00%
Return on Assets8.00%
Return on Sales22.00%
Gross margin (latest quarter)56.42%
EBITDA$272.80M
Trading
Average volume823,276
Dividend
Ex dividend date27 Aug 2026
Last payment date15 Sep 2026
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.91
- MACD 12/26/9
- 0.13
- EMA 9 of MACD
- 0.17
- MACD histogram
- -0.04
- SMA 50
- $5.94
- Price above SMA 50
- EMA 50
- $5.93
- Price above EMA 50
- SMA 200
- $6.22
- Price above SMA 200
- EMA 200
- $7.12
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -0.2 | -21.9 | +0.2 | +12.8 | +8.1 | -10.0 | +9.6 | +9.6 | -24.0 | |||
| 2023 | +4.3 | +16.8 | -13.4 | +1.8 | -4.4 | -19.6 | +1.6 | -13.4 | -17.5 | +2.9 | +20.9 | +2.8 |
| 2024 | -10.1 | -18.6 | -6.3 | -22.7 | +22.1 | -2.5 | +29.0 | +6.1 | -14.3 | -0.2 | +46.2 | +0.1 |
| 2025 | -11.5 | -24.8 | -0.9 | -3.5 | -14.3 | -7.3 | -1.0 | +45.4 | -3.5 | -9.3 | -4.9 | -3.0 |
| 2026 | -9.0 | -6.2 | -11.5 | +4.1 | -63.4 | -0.9 | +8.3 | +38.2 | +7.8 | +7.9 | +5.5 |
Corporate actions
Upcoming
No upcoming corporate actions for EMBC
Past
DividendQ3/26
Ex-dividend date27 Aug 2026
Payable date15 Sep 2026
Amount per share$0.01
DividendQ2/26
Ex-dividend date28 May 2026
Payable date15 Jun 2026
Amount per share$0.01
DividendQ1/26
Ex-dividend date27 Feb 2026
Payable date17 Mar 2026
Amount per share$0.15
DividendQ4/25
Ex-dividend date5 Dec 2025
Payable date18 Dec 2025
Amount per share$0.15
DividendQ3/25
Ex-dividend date29 Aug 2025
Payable date15 Sep 2025
Amount per share$0.15
DividendQ2/25
Ex-dividend date28 May 2025
Payable date13 Jun 2025
Amount per share$0.15
DividendQ1/25
Ex-dividend date28 Feb 2025
Payable date14 Mar 2025
Amount per share$0.15
DividendQ4/24
Ex-dividend date6 Dec 2024
Payable date18 Dec 2024
Amount per share$0.15
DividendQ3/24
Ex-dividend date27 Aug 2024
Payable date13 Sep 2024
Amount per share$0.15
DividendQ2/24
Ex-dividend date24 May 2024
Payable date14 Jun 2024
Amount per share$0.15
DividendQ1/24
Ex-dividend date27 Feb 2024
Payable date15 Mar 2024
Amount per share$0.15
DividendQ4/23
Ex-dividend date1 Dec 2023
Payable date15 Dec 2023
Amount per share$0.15
DividendQ3/23
Ex-dividend date24 Aug 2023
Payable date13 Sep 2023
Amount per share$0.15
DividendQ2/23
Ex-dividend date25 May 2023
Payable date13 Jun 2023
Amount per share$0.15
DividendQ1/23
Ex-dividend date24 Feb 2023
Payable date13 Mar 2023
Amount per share$0.15
DividendQ4/22
Ex-dividend date29 Dec 2022
Payable date11 Jan 2023
Amount per share$0.15
DividendQ3/22
Ex-dividend date25 Aug 2022
Payable date14 Sep 2022
Amount per share$0.15
Compare stocks
Market cap
$369.99M
-
-
-
Price / Earnings ratio
4.20
-
-
-
Price / Sales ratio
0.35
-
-
-
Dividend yield
4.90%
-
-
-
Average volume
823,276
-
-
-
Earnings per share
$1.50
-
-
-
